Isentress launched in Japan
This article was originally published in Scrip
Executive Summary
Merck & Cohas launched its first-in-class integrase inhibitor for HIV Isentress (raltegravir) in Japan through its local subsidiaryBanyu. The product, which has orphan status, is indicated in combination with other antiretrovirals in adults who have already received treatment, and is reimbursed at ¥1,510.40 ($14.0) per 400mg tablet. The standard dose is one tablet twice a day, which does not have to be taken with food. Isentress was approved in the US last October and in the EU at the beginning of this year.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.